ANIK
Price
$9.02
Change
+$0.02 (+0.22%)
Updated
Sep 26, 12:44 PM (EDT)
Capitalization
129.76M
34 days until earnings call
ORGO
Price
$4.68
Change
-$0.22 (-4.49%)
Updated
Sep 25 closing price
Capitalization
593.69M
40 days until earnings call
Interact to see
Advertisement

ANIK vs ORGO

Header iconANIK vs ORGO Comparison
Open Charts ANIK vs ORGOBanner chart's image
Anika Therapeutics
Price$9.02
Change+$0.02 (+0.22%)
Volume$500
Capitalization129.76M
Organogenesis Holdings
Price$4.68
Change-$0.22 (-4.49%)
Volume$460.21K
Capitalization593.69M
ANIK vs ORGO Comparison Chart in %
Loading...
ANIK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANIK vs. ORGO commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a Buy and ORGO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (ANIK: $9.00 vs. ORGO: $4.68)
Brand notoriety: ANIK and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIK: 53% vs. ORGO: 49%
Market capitalization -- ANIK: $129.76M vs. ORGO: $593.69M
ANIK [@Pharmaceuticals: Generic] is valued at $129.76M. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $593.69M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIK’s FA Score shows that 0 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).

  • ANIK’s FA Score: 0 green, 5 red.
  • ORGO’s FA Score: 1 green, 4 red.
According to our system of comparison, ORGO is a better buy in the long-term than ANIK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIK’s TA Score shows that 3 TA indicator(s) are bullish while ORGO’s TA Score has 4 bullish TA indicator(s).

  • ANIK’s TA Score: 3 bullish, 3 bearish.
  • ORGO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ANIK and ORGO are a good buy in the short-term.

Price Growth

ANIK (@Pharmaceuticals: Generic) experienced а +0.67% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was -1.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.88%. For the same industry, the average monthly price growth was +23.85%, and the average quarterly price growth was +67.10%.

Reported Earning Dates

ANIK is expected to report earnings on Oct 30, 2025.

ORGO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORGO($594M) has a higher market cap than ANIK($130M). ORGO YTD gains are higher at: 46.250 vs. ANIK (-45.322). ORGO has higher annual earnings (EBITDA): 3.19M vs. ANIK (-2.24M). ORGO has more cash in the bank: 73.1M vs. ANIK (53.2M). ANIK has less debt than ORGO: ANIK (25M) vs ORGO (40.8M). ORGO has higher revenues than ANIK: ORGO (429M) vs ANIK (115M).
ANIKORGOANIK / ORGO
Capitalization130M594M22%
EBITDA-2.24M3.19M-70%
Gain YTD-45.32246.250-98%
P/E RatioN/A63.75-
Revenue115M429M27%
Total Cash53.2M73.1M73%
Total Debt25M40.8M61%
FUNDAMENTALS RATINGS
ANIK vs ORGO: Fundamental Ratings
ANIK
ORGO
OUTLOOK RATING
1..100
1080
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
8942
P/E GROWTH RATING
1..100
6910
SEASONALITY SCORE
1..100
2565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (75) in the Financial Conglomerates industry is in the same range as ANIK (92) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's Profit vs Risk Rating (97) in the Financial Conglomerates industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's SMR Rating (94) in the Financial Conglomerates industry is in the same range as ANIK (97) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's Price Growth Rating (42) in the Financial Conglomerates industry is somewhat better than the same rating for ANIK (89) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew somewhat faster than ANIK’s over the last 12 months.

ORGO's P/E Growth Rating (10) in the Financial Conglomerates industry is somewhat better than the same rating for ANIK (69) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew somewhat faster than ANIK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIKORGO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
64%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ANIK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KKPNF4.810.11
+2.34%
Royal KPN NV
AALBF34.57N/A
N/A
A. Alberts Industries
CYYHF0.27N/A
N/A
China Yongda Automobile Svcs Hldgs Ltd.
NOSUF0.01N/A
N/A
Nerds On Site Inc.
INNPD7.47N/A
N/A
Innocan Pharma Corp.

ANIK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIK
1D Price
Change %
ANIK100%
-0.77%
RVTY - ANIK
39%
Loosely correlated
-1.72%
AVNS - ANIK
35%
Loosely correlated
-4.55%
ACRS - ANIK
34%
Loosely correlated
N/A
ORGO - ANIK
33%
Poorly correlated
-4.49%
FLGT - ANIK
32%
Poorly correlated
-0.32%
More

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-4.49%
ANIP - ORGO
49%
Loosely correlated
-1.71%
PRGO - ORGO
46%
Loosely correlated
-2.95%
ANIK - ORGO
33%
Poorly correlated
-0.77%
ACET - ORGO
29%
Poorly correlated
-1.86%
AMRX - ORGO
29%
Poorly correlated
-1.13%
More